Vera Therapeutics Inc.
1 products tracked · names used in filings: Vera Therapeutics Inc., Vera Therapeutics, Inc.
Upcoming milestones
No upcoming milestones listed.
Recent milestones
atacicept: PDUFA target action date (IgA Nephropathy (IgAN) in adults)
Vera Therapeutics, Inc. (VERA); atacicept; BLA; status: set; "Food and Drug Administration (FDA) granted priority review to Biologics License Application (BLA) for the accelerated approval of atacicept in adult patients with IgA Nephropathy (IgAN) with a Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 • On track for U.S."; filed 2026-05-07 · source
FDA approves Trutakna (atacicept-vymj), a new medicine
Vera Therapeutics Inc.; BLA761486; New biologic, Priority review; injectable · source
Vera Therapeutics, Inc.: PDUFA target action date
Vera Therapeutics, Inc. (VERA); "(Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today reported its business highlights and financial results for the first quarter ended March 31, 2025."; filed 2025-05-06 · source
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇺🇸 | Trutakna atacicept-vymj | Approved | 2026-07-07 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.